|Dr. Dolores J. Schendel||CEO, Chief Scientific Officer & Member of Exec. Management Board||N/A||N/A||N/A|
|Mr. Axel Sven Malkomes||CFO, Chief Bus. Devel. Officer & Member of Exec. Management Board||N/A||N/A||N/A|
|Dr. Kai Pinkernell||Chief Medical Officer, Chief Devel. Officer & Member of Exec. Management Board||N/A||N/A||N/A|
|Dr. Ernst-Ludwig Winnacker||Co-Founder & Chairman Scientific Advisory Board||N/A||N/A||1941|
|Dr. Gary Anthony Waanders Ph.D.||VP of Investor Relations||N/A||N/A||N/A|
Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al and Institute for Research in Immunology and Cancer Â Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Medigene AG’s ISS Governance QualityScore as of December 1, 2020 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 5.